Open AccessThe Role and Clinical Significance of Yes-Associated Protein 1 in Human Osteosarcoma
Author(s) -
Zhang Yh,
Li B,
Lisong Shen,
Yinghui Shen,
X-D Chen
Publication year - 2013
Publication title -
international journal of immunopathology and pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.724
H-Index - 53
eISSN - 2058-7384
pISSN - 0394-6320
DOI - 10.1177/039463201302600115
Subject(s) - yap1 , gene knockdown , oncogene , cancer research , downregulation and upregulation , osteosarcoma , tissue microarray , carcinogenesis , immunohistochemistry , biology , cancer , cell growth , medicine , chemistry , pathology , microbiology and biotechnology , cell cycle , cell culture , transcription factor , gene , genetics
Yes-associated protein 1 (YAP1) is an oncogene that plays multiple roles in the tumorigenesis and progression of many malignances. The present study aimed to investigate the clinical significance of YAP1 expression in human osteosarcoma (OS) and explore the molecular mechanisms of YAP1 activity in OS MG-63 cells. The expression of YAP1 was assessed by immunohistochemical assay using a tissue microarray procedure. A loss-of-function approach was used to investigate the effects of small hairpin RNA-mediated knockdown of YAP1 on the expression of RUNX2, CyclinD1, and matrix metalloproteinase-9 (MMP-9) as well as the proliferative activities and invasive potential in OS MG-63 cells (evaluated by MTT and Transwell assays, respectively). The expression of YAP1 protein in OS tissues was significantly higher than that in ANCT, and was closely associated with gender ( P = 0.013) and Enneking staging ( P = 0.035), but it did not correlate with age, tumor location, or distant metastases of OS patients ( P > 0.05, each). Knockdown of YAP1 resulted in downregulation of the expression of RUNX2, CyclinD1, and MMP-9 and inhibited the proliferation and invasion of MG-63 cells. Our findings suggest that YAP1 is highly expressed in OS tissues, and increased expression of this molecule is correlated with the gender and Enneking staging of osteosarcoma patients. Knockdown of YAP1 may inhibit the proliferation and invasion of OS cells through downregulation of the RUNX2 pathway, thereby representing a potential therapeutic target for the treatment of cancer.